Results from a recent clinical trial indicate that denosumab delayed the spread of prostate cancer metastases bones, however it did not prolong the lives of men. […]
Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
This has been an interesting year as men with advanced prostate cancer have seen three different drugs approved. Considering that the prior six years did not have any new drug approvals, this has been a stellar year. First we had Provenge approved, then came Jevtana and now we have added to the list Xgeya (denosumb). [...]
Although some people have called it intriguing, a new “On The Horizon” drug, XL-184, is still very early in its testing. What makes LX184 intriguing is the just released results from a conference in Berlin. In very early testing, 19 of 20 men in a phase I trial showed an improvement in their scans used [...]
For men with advanced prostate cancer adjuvant radiation therapy improves the cancer-specific survival of men with seminal vesicle invasion, even in the presence of nodal metastases. This underscores the need for multi-modal treatment approaches in advanced prostate cancer patients. Joel T. Nowak, M.A., M.S.W.